Subtitle 1: Targeting the Unmet Needs of the Non-Steroidal TSW Treatment Market

Codex Labs Corp. will participate as a sponsor and exhibitor at the 2026 TSW Summit, hosted by the International Topical Steroid Awareness Network (ITSAN), to enhance brand awareness. Topical Steroid Withdrawal (TSW) is a severe systemic skin inflammation that occurs when long-term use of steroids for conditions like atopic dermatitis is discontinued. With the global atopic dermatitis treatment market projected to reach up to $22.94 billion by 2026, there is a significant unmet need for non-steroidal skincare products that can replace steroids, which are associated with potential side effects. Through its participation in this event, Codex Labs aims to establish strong brand credibility within the TSW patient community and solidify its position in the non-steroidal solution market.

Subtitle 2: Accelerating Commercialization through the Pre-Launch of 'Bia Eczema Soothing Oil'

The highlight of the summit will be the pre-launch of 'Bia Eczema Soothing Oil,' a prototype of the new product scheduled for official commercial release in October. This is more than just a new product promotion; it is a strategic move to gather feedback from potential customers and medical professionals before the actual product launch and accelerate market penetration. TSW patients have compromised skin barriers and are highly sensitive, making initial trust formation crucial for driving sales. Therefore, Codex Labs aims to leverage the pre-launch promotion to generate positive word-of-mouth about the product's efficacy and aggressively capture initial market share upon launch.

Subtitle 3: Collaboration on Clinical Research and Scientific Validation of Skin Barrier Recovery Protocols

Codex Labs will present the results of a TSW clinical case study conducted in collaboration with leading experts such as Dr. Ian Myles of the National Institute of Allergy and Infectious Diseases (NIAID) and Dr. Peter Lio of Northwestern University. This study validated the positive effects of an integrated portfolio, including Bia Eczema Soothing Oil, Bia GutBuilder, Bia Unscented Soap, and Kangfu gel, on active skin healing and barrier restoration in TSW patients. Objective clinical evidence will be a critical marketing asset in the dermocosmetic market, which values scientific validation, and will help build high trust among consumers and prescribing physicians, comparable to regulatory approvals.

Subtitle 4: Expanding the Next-Generation Skin Disease Portfolio Based on the 'Gut-Skin Axis'

This presentation will showcase Codex Labs' next-generation research direction, which is based on the 'Gut-Skin Axis' theory, which explores the relationship between gut microbiota and skin immunity. Following the existing Bia Collection for atopic dermatitis and the Kangfu gel for skin healing, Codex Labs is offering a comprehensive barrier recovery protocol that combines gut health supplements and a dedicated soothing oil, aiming to differentiate itself in the market. This represents a completely new treatment paradigm that can supplement or replace the long-term side effects caused by steroid treatment, and it will be a significant milestone in the company's pipeline expansion and long-term corporate value enhancement.